|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.00 GBX | +0.75% |
|
+5.93% | +54.02% |
| Sep. 17 | Diaceutics PLC, Q2 2024 Earnings Call, Sep 17, 2024 | |
| Sep. 17 | Diaceutics PLC, Q2 2024 Earnings Call, Sep 17, 2024 |
| Capitalization | 112M 149M | P/E ratio 2024 * |
-83.6x | P/E ratio 2025 * | 70.9x |
|---|---|---|---|---|---|
| Enterprise value | 56.65M 75.39M | EV / Sales 2024 * |
3.32x | EV / Sales 2025 * | 2.6x |
| Free-Float |
65.7% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Diaceutics PLC
More press releases
| 1 day | +0.41% | ||
| 1 week | +5.57% | ||
| Current month | +0.79% | ||
| 1 month | +4.34% | ||
| 3 months | +13.18% | ||
| 6 months | +31.58% | ||
| Current year | +53.51% |
1 week
123.00
135.00
1 month
122.12135.00
Current year
84.50136.00
1 year
82.00136.00
3 years
74.00136.00
5 years
74.00195.00
10 years
74.00195.00
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 40 | 08-05-31 |
Nick Roberts
DFI | Director of Finance/CFO | - | 22-03-17 |
Julie Browne
COO | Chief Operating Officer | - | 22-03-14 |
| Manager | Title | Age | Since |
|---|---|---|---|
Peter Keeling
BRD | Director/Board Member | 63 | 04-12-31 |
Ryan Keeling
CEO | Chief Executive Officer | 40 | 08-05-31 |
Michael Wort
BRD | Director/Board Member | 73 | 19-03-13 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.41% | +5.57% | +26.59% | +19.78% | 149M | ||
| +1.61% | +2.63% | +45.69% | +88.38% | 4.56B | ||
| +0.61% | +1.27% | +75.00% | +25.20% | 2.61B | ||
| -0.63% | +1.64% | -14.40% | -29.47% | 2.41B | ||
| -2.18% | +2.39% | -14.58% | -37.88% | 2.21B | ||
| -0.50% | -10.41% | +44.42% | +468.29% | 1.93B | ||
| +3.80% | +1.33% | -31.75% | -37.15% | 1.29B | ||
| +0.74% | -1.81% | -36.04% | -40.78% | 1.24B | ||
| +2.45% | +0.91% | -14.61% | -27.05% | 1.13B | ||
| +2.46% | +2.11% | -22.81% | +5.82% | 897M | ||
| Average | +0.88% | +0.34% | +5.75% | +43.51% | 1.84B | |
| Weighted average by Cap. | +0.68% | +0.31% | +16.52% | +59.49% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 29.83M 39.7M | 37.75M 50.25M |
| Net income | -1.8M -2.39M | 1.02M 1.36M |
| Net Debt | -13.27M -17.66M | -14.27M -18.98M |
More financial data
* Estimated data
Employees
184
Sector
Business Support Services
Calendar
2025-03-24
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-20 | 134.00 p | +0.75% | 24,928 |
| 24-09-19 | 133.00 p | -0.75% | 1,300,101 |
| 24-09-18 | 134.00 p | +1.13% | 170,668 |
| 24-09-17 | 132.50 p | +3.92% | 471,932 |
| 24-09-16 | 127.50 p | +0.79% | 16,016 |
Delayed Quote London S.E., September 20, 2024 at 08:09 am EDT
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.330GBP
Average target price
1.746GBP
Spread / Average Target
+31.28%
- Stock Market
- Equities
- DXRX Stock
